Premium
Oral malignant melanoma – the effect of coarse fractionation radiotherapy alone or with adjuvant carboplatin therapy
Author(s) -
Murphy S.,
Hayes A. M.,
Blackwood L.,
Maglen G.,
Pattinson H.,
Sparkes A. H.
Publication year - 2005
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/j.1476-5810.2005.00082.x
Subject(s) - carboplatin , medicine , radiation therapy , melanoma , lymph node , adjuvant therapy , adjuvant , chemotherapy , oncology , cisplatin , cancer research
A retrospective study was undertaken of dogs presented to the Animal Health Trust for treatment of oral malignant melanoma, without radiographic evidence of pulmonary metastases. Group 1 ( n = 13) received radiotherapy of the primary and any lymph node metastases (4 weekly fractions of 9 Gy); and group 2 ( n = 15) were treated the same but additionally received between two and six doses carboplatin at 300 mg m −2 every 3 weeks. Median survival times for the two groups were 307 and 286 days, respectively ( P > 0.05). In addition, carboplatin therapy did not significantly reduce the proportion of dogs dying due to metastases (three from group 1 and four from group 2). We found no evidence of a beneficial effect of carboplatin therapy over radiotherapy alone.